T he ability to sustain T cell function despite persistent antigen stimulation contributes to the clearance of both chronic infection and cancer. However, when T cell immunity targets self antigen or excessively damages healthy tissue, maintaining robust responses can prove harmful rather than helpful. T cell exhaustion has emerged as a key mechanism through which CD8 + T cells lose effector ability during persistent stimulation; it not only curtails their ability to cause damaging immunopathology but also facilitates viral persistence or hinders tumor-targeted responses. A substantial body of work studying mouse models of chronic infection with lymphocytic choriomeningitis virus (LCMV) has identified the molecular, transcriptional and functional basis of T cell exhaustion. Studies have implicated in early metabolic signaling during T cell activation in the later development of exhaustion. In doing so, such work has highlighted the potential for metabolic signals to shape T cell differentiation and has focused attention on the potential of immunometabolic therapy in multiple contexts.
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T cell differentiation and metabolism
The activation and differentiation of T cells involves rapid proliferation, cytokine production and development of cytotoxic effector function. For this to happen, cells must balance increasing energy demands with an increasing need for substrates to allow growth and division. The bioenergetic needs of naive or quiescent T cells are met mainly by mitochondrial oxidative phosphorylation (OXPHOS), an efficient means of generating ATP from a glucose substrate 1 . After activation, however, there is a switch to aerobic glycolysis 2 , known as the 'Warburg effect'; this is a comparatively inefficient process in which fewer ATP molecules are generated per molecule of glucose processed 3 . A T cell's 'choice' of aerobic glycolysis initially makes little sense, as it is not only inefficient but also seemingly unnecessary; cells switch to glycolysis even when abundant oxygen is available. However, the trade-off is that a greater number of metabolic intermediates are produced for anabolic growth, including those for the synthesis of nucleotides and amino acids 4 , the maintenance of cellular redox balance (NAD + /NADH) 5 and the production of acetyl-CoA for lipid synthesis through the processing of citrate 6 . The switch to aerobic glycolysis is also required for the development of full effector function (release of the cytokines IL-2 and IFN-γ ), as the glycolytic enzyme GAPDH otherwise restricts the translation of IFN-γ mRNA 2 . However, effector differentiation is not the only goal of T cell activation, and the switch to aerobic glycolysis is not complete 2 . After encounter with and eradication of antigen, an expanded, persistent population of memory T cells shows a faster, more robust response to subsequent activation (Fig. 1 ). For such memory to develop during a primary T cell burst, aerobic glycolysis-driven effector function must be balanced with other metabolic pathways, including OXPHOS 7 and fatty-acid oxidation (FAO) 8, 9 . A central role for mitochondria in this balance has been highlighted by considerable dynamic changes in their ultrastructure: memory T cells show fusion of mitochondrial cristae into networks, whereas their effector counterparts (effector T cell populations) undergo fission and remain expanded 10 . The mature memory phenotype is also fueled by an increased mitochondrial biomass 11 and spare respiratory capacity, driven by IL-15-mediated upregulation of carnitine palmitoyltransferase (CPT1a) 7 . The activity of CPT1a controls mitochondrial FAO and fosters the ability to generate a stronger, longer burst of both aerobic glycolysis and OXPHOS after restimulation 11 . However, we note that the role of FAO has been demonstrated through the use of pharmacological inhibition of CPT1a, whose specificity has been brought into question by gene-deletion studies 12 . Much complexity surrounding the role of FAO in T cell differentiation remains to be 'unpicked' .
It is to be expected that dynamic metabolic changes must occur to keep pace with the rapid changes in cellular function that accompany T cell activation 13 . However, the studies noted above have together identified cellular metabolism, and mitochondrial biomass and function in particular, as key drivers of T cell phenotype, rather than as simply reflecting changes in energy demand during differentiation 8, 14 . With immunometabolism taking center stage, it has now become clear that the development and maintenance of T cell exhaustion are also under metabolic regulation.
Exhaustion and metabolism
T cell exhaustion is associated with progressive dysfunction characterized by limited proliferation, cytokine production and effector capacity that is driven by persistent, high levels of antigen exposure and a relative lack of costimulatory 'help' signals 15 . Exhaustion was originally identified in the mouse LCMV model of chronic viral infection but has since been identified during numerous other chronic infections, in the tumor microenvironment and during autoinflammatory responses 16, 17 . Its development controls the persistence and outcome of cellular immunity to persistent antigen and has been associated with disease outcome in each case 15, 17 . Subsequent work has demonstrated that exhaustion is also associated with substantial bioenergetic compromise in the setting of both chronic viral infection and the tumor microenvironment [18] [19] [20] . The observed metabolic dysfunction precedes the development of exhaustion itself and has been mechanistically linked to early inhibitory signals from the immunoregulatory receptor PD1. However, this is only one part of the complex cascade that modulates metabolism and the balance of effector function, cellular survival and exhaustion. So far, studies have focused on catabolic metabolism and mitochondrial function and on the pathways that control them. Consequently, this Review is similarly focused, but this should not be taken as precluding the possibility of an important role for downstream synthetic pathways.
In the LCMV model of chronic viral infection, late emergence of T cell dysfunction is preceded by both transcriptional changes and functional changes, suggestive of glucose deprivation, with suppression of both glycolysis and OXPHOS 18, 21 . Glucose transport is limited in early exhaustion, with downregulation of transport mediated by the glucose transporter GLUT1. However, alterations in glucose uptake have been seen to be modest, which has prompted a search for changes in mitochondrial mass and function. This has shown that the mitochondria of exhausted T cells (T exh cells) are larger but dysfunctional. The increased mitochondrial biomass is accompanied by a paradoxical decrease in mitochondrial function (oxygen-consumption rate) and by an increase in both mitochondrial depolarization and the production of reactive oxygen species (ROS) in T exh cells relative to that of their effector counterparts (effector T cells). Ultrastructural changes in the mitochondria, including elongation of cristae, are also apparent 18 , although it is less clear how these relate to ultrastructural changes already known to distinguish classic memory cell populations from effector cell populations 10 . It is challenging, particularly in vivo, to quantify the degree of metabolic switching needed to induce these mitochondrial changes (as it is with associated parameters, such as spare respiratory capacity) 7 and thus to understand their importance in directing T cell fate. CD8 + tumor-infiltrating lymphocytes (TILs) also exhibit an exhausted phenotype 22, 23 that limits anti-tumor responses and can be reversed by cancer immunotherapy with impressive results 16 .
As noted for T exh cells during chronic infection with LCMV, TIL exhaustion in multiple mouse models has shown evidence of glucose deprivation and mitochondrial dysfunction. As with T exh cells in the LCMV model, reduced uptake of glucose by TILs is matched by diminished mitochondrial function (oxygen-consumption rate) and increased depolarization 19, 20 . However, while the bioenergetic changes to T exh cells are broadly similar in both TIL models and models of chronic viral infection, there are also differences. Whereas T exh cells during infection with LCMV show greater mitochondrial biomass and increased ROS production 18 , TILs show a reduction in both 19 . The apparent contribution of PD1 signaling to metabolic dysfunction is also different in the two contexts. The early metabolic dysfunction of T exh cells during infection with LCMV strain clone 13 (LCMV-cl13) responds to either genetic deletion of PD1 (adoptive transfer of Pdcd1 −/− P14 T cells, which have transgenic expression of an LCMV-specific T cell antigen receptor (TCR)) or to blockade of the PD1 ligand PDL1 18, 19 . However, mitochondrial biomass in TILs is not substantially altered by blockade of PD1, even though such blockade results in effective tumor regression 19 . Such context-specific differences in the metabolic features of exhaustion require further investigation, but some explanations can be offered on the basis of increasing appreciation of the metabolic factors that control the effector function, survival and exhaustion of T cells.
The availability of metabolic substrates and exhaustion: Goldilocks and the three substrates
Emerging evidence has identified several metabolic pathways as important participants in the development of T cell exhaustion. However, we note that, as with their contribution to T cell differentiation more broadly, their respective roles are actually integrated, with changes in one influencing many others.
Hypoxia and exhaustion
Both the metabolic dysfunction and effector dysfunction of TILs are clearly driven by and restricted to the tumor microenvironment 19, 20, 22, 23 . The local availability of metabolic substrates is an important factor that shapes exhaustion and might also explain some of the variation between exhaustion models in their metabolic parameters (Fig. 2) .
It has long been known that the tumor microenvironment is hypoxic and that this favors tumor growth 24 . However, studies have revealed the importance of hypoxia in driving the metabolic dysfunction of exhaustion. The tumor suppressor Vhl does not interact with subunits of the transcription factor Hif ('hypoxia-inducible factor') under hypoxic conditions, which allows Hif to translocate to the nucleus and mediate transcription of its target genes. Genetic deletion of Vhl unleashes the activity of Hif during persistent T cell responses and results in fatal immunopathology during chronic infection with LCMV but improves survival in an experimental melanoma model, as T cells maintain effector function instead of undergoing exhaustion 25 . Such work further supports the prevailing theory that exhaustion has evolved as a mechanism by which chronic infection is 'tolerated' by the host, rather than the host's risking fatal injury during an attempt to clear it 17 . It also highlights the importance of the hypoxia-Vhl-Hif pathway in controlling the effector function of T cells during persistent antigen stimulation. A metabolomic study of Vhl-deficient mouse CD8
+ T cells (with consequent high levels of Hif activity) subsequently identified S-2-hydroxyglutarate (S2HG) as a key immunometabolite that controls the persistent activity of cytotoxic T lymphocytes in both immunization models and tumor models 26 . S2HG levels are increased by stimulation via the TCR in a Hif-dependent fashion but might also be influenced by other metabolic pathways, including glutaminolysis, that promote both effector differentiation and the persistence of effector T cells 26 . It also appears that the contribution of hypoxic Vhl-Hif signaling to exhaustion is distinct from the contribution of classic inhibitory receptors. In the absence of Vhl (Vhl −/− P14 T cells in the LCMV-cl13 model), classic inhibitory receptors such as LAG3 and PD1 are still induced during chronic infection but exhaustion does not develop, which results in lethal immunopathology driven by an aggressive response by CD8 + cytotoxic T lymphocytes. Hypoxia is a constant presence in conditions of rapid infiltration, proliferation and activation of T cells whether in the tumor microenvironment or virus-infected tissue or in the context of autoinflammatory disease. It is clear that the metabolic response of a T cell to such hypoxic microenvironments is an important determinant of its ability to sustain an effector response and, consequently, of the disease outcome. However, the exact effect of hypoxia on the effector function of T cells remains unclear, with some studies suggesting that limiting Hif expression (by knockdown rather than genetic deletion) can improve rather than attenuate effector capacity 27 .
Glucose and exhaustion
T cell activation is characterized by aerobic glycolysis; that is, the switch away from OXPHOS despite the presence of sufficient oxygen to maintain it 13 . However, a lack of glucose availability in, or a lack of its uptake from, the microenvironment does have important consequences for persistence of the effector function of T cells (Fig. 3, left) . Some studies have suggested that limiting glycolysis can favor OXPHOS-mediated memory formation and enhanced persistent effector function 28 , although others have demonstrated a need for ongoing glycolysis to maintain effector function 29 . This apparent discrepancy reflects a need for glycolysis-driven effector function to be counterbalanced by concurrent memory formation, driven by alternative metabolic pathways such as Hif, FAO and OXPHOS. At least some glycolysis is clearly required for the initial activation of T cells and for the development and maintenance of proliferation and effector function 2, 13 . Similarly, even in the setting of enforced constitutive glycolysis (achieved through conditional deletion of Vhl), a long-lived memory population does develop, albeit one that is skewed toward an effector-memory phenotype 29 . Balanced contributions from both effector-associated glycolysis and memorypromoting metabolism such as FAO and OXPHOS are required for optimal T cell-mediated control of a pathogen or tumor 30 . Skewing the response too far in either direction could hamper persistent effector function.
T exh cells do show an early reduction in GLUT1-mediated uptake of glucose and early gene-expression profiles consistent with glucose deprivation 18, 19, 31 . When TILs or T exh cells from mice chronically infected with LCMV are exposed to conditions of glucose deprivation, they show attenuation of signaling via both the TCR and the NFAT family of transcription factors, with associated defects in Ca 2+ flux, akin to those that characterize T cell anergy 31, 32 . Altered levels of the glycolytic metabolite phosphoenolpyruvate (PEP) 31 in T exh cells also contribute to the observed metabolic and effector dysfunction and do not simply reflect secondary changes in metabolism. Glycolysis-induced accumulation of PEP has been identified as being needed to sustain both Ca 2+ and NFAT signaling, and, hence, effector function, after activation via the TCR, with a loss of expression of IFN-γ and the B cell-stimulatory molecule CD40L when it is suppressed 31 . The same study 31 also provides a reminder that cells are continually competing for metabolic substrates in their local microenvironment, and that it is not just a T cell's ability to take up and use a substrate that determines metabolic fitness, but that the competing ability of neighboring cells might be just as important. Overexpression of the enzyme hexokinase-2 in tumor cells increases their rate of glycolysis, with evidence of glucose deprivation developing in TILs as a consequence 31 . Such competition for substrates has been elegantly demonstrated in the tumor microenvironment, where tumor cell-driven changes in the availability of glucose are reflected in a reduction in the effector capacity of TILs 20 . A decrease in tumor-cell glycolysis might explain at least in part the reversal of TIL exhaustion and the success of blocking 'checkpoint' inhibitory receptors 20 . The degree to which such competition for substrates contributes to exhaustion in the context of either chronic infection or autoimmune responses is less clear, although it very probably has role.
amino acids, survival and effector differentiation
Enhanced T cell survival in an exhausting tumor microenvironment has also been shown through increased uptake and metabolism of l-arginine, which usually undergoes specific depletion during T cell activation 33 . Increased l-arginine correlates with improved T cell survival, with differentiation skewed toward the replicative, CCR7
+ central-memory T cell phenotype (Fig. 3, right) . Once again, availability of the metabolic substrate controls the response, as restoring the depleted l-arginine improves cytotoxic capacity both in vitro and in vivo 33 . And once again, enhanced memory differentiation is associated with attenuation of effector function, in this case a reduction in IFN-γ production (although, consistent with memory differentiation, equivalent levels are produced after secondary restimulation) 33 . Cellular uptake of other amino acids, such as the uptake of leucine 34 and glutamine 35 via the amino acid transporters slc7a5 and ASCT2, respectively, is important for the initiation, maintenance and integration of TCR signaling with the downstream metabolic sensor mTOR ('mechanistic target of rapamycin'). Expression of such transporters and amino acid availability are probably also involved, although they have not as yet been investigated in the context of exhaustion. The critical amino acid transporter CD98, a downstream target of the metabolic regulator c-Myc 36 and a heterodimer that incorporates slc7a5, does show elevated expression on memory CD8
+ T cells but not on exhausted CD8
+ T cells during chronic infection 37 . Together these data make it clear that competition for metabolic substrates within the local microenvironment is a critical factor that influences the balance of effector function and T cell persistence during exhaustion 19, 20, 31 .
Metabolic exhaustion in different models: the same but different
The majority of studies so far have consistently demonstrated metabolic dysfunction preceding exhaustion in different contexts. Furthermore, the observations are not restricted to murine models of disease. TILs from human cancer have been shown to have a similarly dysfunctional metabolic phenotype 19, 38 , while human CD8 + T cells specific for chronic persistent viral infection (with hepatitis B virus) 39, 40 , but not those specific for acute viral infection (with influenza virus) 40 or recurrent viral infection (cytomegalovirus) 39 , have been shown to have similar limitations in glucose uptake and mitochondrial biomass.
However, while the bioenergetic changes in T exh cells seem to be broadly similar in both TIL models and models of chronic viral infection, there are also differences. Whereas T exh cells during chronic infection with LCMV show greater mitochondrial biomass and increased ROS production 18 , TILs show a reduction in both 19 . The apparent contribution of PD1 signaling to metabolic dysfunction is also different in the two contexts. The early metabolic dysfunction of T exh cells during infection with LCMV-cl13 responds to either genetic deletion of PD1 (adoptive transfer of Pdcd1 −/− P14 (LCMV-specific) T cells) or to blockade of PDL1 18, 19 . However, mitochondrial biomass in TILs is not substantially altered by blockade of PD1, even though such blockade results in effective regression of the tumor 19 . Sampling of T cells at different stages of exhaustion (a dynamic process that reflects a continuum of dysfunction 41 ) and from microenvironments comprising different substrate availabilities might explain at least some of the variance observed. However, other factors might also contribute to this. T exh cells are known to be heterogeneous, with two principal subsets defined by both their expression of PD1 and their reciprocal expression of the transcription factors Tbet and Eomes hi subset has been shown to have more severe metabolic dysfunction consistent with its 'terminally exhausted' phenotype. The distribution of these subsets among TIL populations is not currently clear 19, 38 , but the lack of a metabolic response to blockade of PD1 19 suggests they probably show enrichment for 'terminally exhausted' cells. The observation that adoptive transfer of TILs into a setting of acute viral infection (with ovalbumin-expressing vaccinia virus) fails to restore their function is consistent with such a proposal 19 . Despite that, a 'bioenergetic revival' after blockade of PD1, such as that seen during chronic infection 18 , might still occur in tumor models and contribute to restoration of tumoricidal function. However, it might be occurring outside the tumor microenvironment in less terminally exhausted T cells and consequently might not be visible within it.
Exhaustion is a spectrum rather than a binary state 15 , and both its extent and the nature of its induction might differ depending on the context. TILs show an exhausted phenotype only within the tumor microenvironment and remain fully functional in the periphery of tumor-bearing mice 15, 19 or in human cancer 22, 38 . Indeed, the metabolic dysfunction of TILs cannot be reproduced by co-culture of CD8 + T cells with isolated tumor cells in vitro 19 , indicative of an important and complex role for the microenvironment in its induction. In contrast, exhaustion is apparently different between different mice rather than between different anatomical locations in the same mouse 43 . Mice that receive the clone 13 strain of LCMV develop chronic infection and exhaustion, while those that receive the highly related Armstrong strain have robust memory differentiation after an acute, self-terminating infection.
It is clear that T cell bioenergetics vary markedly between different tissues during infection 18, 19 and also between distinct tumor models 19 , which highlights the importance of context in their development and maintenance. Given evidence demonstrating the importance of local microenvironmental signals, substrate availability and the phenotype of neighboring cell types (both immune and stromal), it is less surprising that, in different contexts, T cells come to be exhausted by different paths.
Early T cell metabolism might control exhaustion, but what controls early T cell metabolism?
Multiple lines of evidence support the assertion that metabolic pathways control the development of T cell exhaustion, although the exact mechanisms of this in vivo remain to be fully elucidated. But what signals control those metabolic pathways early after activation? A series of elegant studies has now identified the main signaling pathways that control the balance between effector differentiation and memory differentiation. Subsequently, these pathways have been investigated in both TIL models and chronic infection models of T cell exhaustion, indicative of an important role there also.
During the activation and proliferation of T cells, the intracellular serine-threonine kinase mTOR integrates diverse environmental signals, including those derived from nutrient, cytokine and TCR signaling pathways 44 . Effector differentiation is favored by TCR-triggered activity of the kinases PI3K and Akt, which drives mTOR-dependent 14 inactivation of the transcription factor FOXO1 45 . FOXO1 serves to repress effector function and promote memory formation by increasing expression of the transcription factor Eomes and by concurrently repressing Tbet 46 . In the presence of TCR signals, such inactivation of FOXO1 tips this balance toward Tbet-mediated effector differentiation (Fig. 4) . It is also clear that many signals feed into this complex junction, including those dependent on the local availability of the metabolic substrates considered above, including hypoxia, glucose, immunometabolites such as S2HG, PEP, and amino acids such as l-arginine 25, 29, 31, 33 .
Inhibitory receptor control: PD1 and T cell metabolism
It is now becoming apparent that early signaling via inhibitory receptors in activated T cells can modulate T cell metabolism to influence the later development of exhaustion. It has long been known that T cell exhaustion is driven by high levels of sustained TCR signaling 41, 47 . However, published work has shown that despite ongoing antigen exposure and TCR triggering, downstream PI3K-AKT-mTOR signaling in exhaustion is not similarly sustained in other words, persistent antigen might drive exhaustion, but this does not correspond to persistent downstream TCR signaling. PD1 expression on antigen-stimulated cells is induced by TCR signaling through NFATc [49] [50] [51] . However, ligation of PD1 is able to 'desensitize' the TCR signal (reducing downstream signaling for a given level of stimulation), which allows a degree of ongoing nuclear activity of FOXO1 that in turn sustains both further PD1 expression and ongoing TCR desensitization 48 . This establishes a self-reinforcing cycle that restrains the development of full effector function with an associated switch away from aerobic glycolytic metabolism 48, 52 . The data discussed above suggest that persistent PD1 signaling actually facilitates T cell survival in the face of a persistent antigenic stimulus. By desensitizing TCR signals, PD1 might actually serve to maintain a degree of bioenergetic fitness in the face of persistent antigen exposure. Exhausted T cells do show evidence of metabolic dysfunction 18, 19 . However, without persistent PD1 signaling, this could be much worse. PD1 can therefore act to facilitate an ongoing, if attenuated, T cell response in the context of persistent activation of the TCR 48 . This system is complex, however; genetic deletion of PD1 (Pdcd1 −/− ) can counterintuitively allow the later accumulation of 'terminally exhausted' cells 53 . However, the details of how PD1 facilitates survival with attenuated function remain unclear and its effects probably vary with the time after stimulation (early versus late; discussed in the subsection on the transcriptional coactivator PGC1a below).
Such a role for PD1 in T cell differentiation also makes evolutionary sense. It is likely that exhaustion has evolved as a means of carefully balancing control of chronic infection with the risk of damaging immunopathology 17 . During acute T cell activation, a feedback loop is established whereby strong TCR signals drive Akt-mediated cytotoxicity (Fig. 4) but also drive PD1 expression, which limits that TCR signaling. Should TCR signals persist, they will be desensitized by PD1, which will allow preservation of bioenergetic fitness sufficient to sustain a longer-term, albeit more restrained, T cell response.
Such insights into the metabolic control of T cell exhaustion have important implications for the design of therapies aimed at its modulation. This schema might also initially seem at odds with observation that blockade of PD1 can promote the restoration of cytotoxicity in both TILs 16 and chronic viral infection 54 . However, PD1-driven desensitization of TCR signals and preservation of some metabolic fitness serves to keep T cells in the fight; the response to persistent antigen is, after all, more of a marathon than a sprint. Reversing exhaustion through blockade of inhibitory receptors has shown much promise as a therapeutic approach in chronic infection or cancer 23, 54, 55 . Blockade of PD1 can clearly induce increased cytotoxicity of exhausted CD8 + T cells. However, if this occurs through promotion of the 'terminal' differentiation of more-cytotoxic Tbet 
PD1
int population 30, 53 , such therapy could effectively undercut the immune system's capacity to maintain an ongoing response. The predicted result would be eradication of the targeted antigen (whether tumor or virus) in some cases in which induced cytoxicity is sufficient but perhaps a 'deeper' state of subsequent exhaustion in which it is not and residual metabolic fitness is lost through blockade of inhibitory receptors.
What is less clear at this stage is exactly how the perpetuating cycle noted above is established in the first place. While the microenvironmental signals discussed above are important, costimulatory signaling very probably also contributes to this. A lack of costimulatory signaling during TCR triggering results in the hyporesponsive state called 'anergy' 32 . Costimulatory signals, such as those received through binding of the costimulatory receptor CD28 56, 57 or through cytokines such as IL-2 58 , are critical for the upregulation of glucose, amino acid transporters and the FAO regulator CPT1a that facilitate the metabolic switch that underlies T cell activation 13, 57 . A failure of such initial costimulation results in comparative metabolic quiescence and anergy 59 . Exhaustion is distinct from anergy: in exhaustion, T cells have received sufficient stimulatory signals to activate, but they continue to receive them and become dysfunctional. However, inadequate costimulation (rather than a lack of costimulation, as in anergy) also contributes to the development of exhaustion 60, 61 and probably promotes the early PD1-driven cycle of bioenergetic compromise that promotes later exhaustion (Fig. 4) .
other inhibitory receptors
Just as the precise nature of the metabolic dysfunction of exhausted cells seems to be different in different contexts (as discussed above), so the mechanism by which it develops might also be distinct. A range of coinhibitory receptors have high expression on exhausted T cells and have distinct but synergistic roles in driving the exhausted phenotype 49 . Mitochondrial dysfunction of TILs is apparent in the tumor microenvironment of multiple mouse models 19, 20, 31 and in human cancers 19, 38 . However, the degree of metabolic dysfunction does not directly parallel the concurrent expression of inhibitory receptors in each context 19, 26 . Exhaustion can clearly develop in the absence of the expression of specific inhibitory receptors 18, 53 , and the expression of inhibitory receptors can be present without the development of exhaustion, such as when Vhl-Hif signaling is absent 25 . Further, whereas metabolic changes are important drivers of exhaustion early during TCR signaling, exhaustion can be reversed at least partially at later stages, with increased cytotoxicity despite no clear modulation of metabolism 18, 19 . Together, these data suggest that multiple redundant signals must contribute to the development of exhaustion and its associated metabolic dysfunction. The summated input from these cell-surface and local environmental signals contribute to the resulting degree of exhaustion.
mTor and metabolism in exhaustion
During T cell activation, mTOR acts to integrate multiple signals including from metabolic, cytokine and TCR signaling pathways 44 . Perhaps unsurprisingly, mTOR activity has therefore been shown to have a central role in T cell metabolism and in exhaustion. However, it was initially a surprise when the immunosuppressive drug rapamycin, an inhibitor of mTOR, was found to promote the memory differentiation of T cells and the associated switch away from aerobic glycolysis toward FAO metabolism 8, 14 . Rapamycin has been used for some time as an immunosuppressive agent able to limit TCR-driven activation and proliferation. However, mTOR has been shown to directly promote the phosphorylation and inactivation of FOXO1 and to promote effector differentiation through downstream Tbet-mediated effects 45, 46, 62, 63 . Early blockade of mTOR in the LCMV-cl13 model of chronic viral infection also modestly improves the mitochondrial fitness of exhausted cells (depolarization and size 18 ), which suggests that chronic mTOR signaling downstream of the TCR can contribute to the metabolic changes of exhaustion, even if TCR signals are 'downtuned' by PD1. It has been observed that blocking mTOR actually impairs the response of TILs to blockade of PD1, which suggests that ongoing mTOR signaling might be needed, at least to some degree, to preserve effector function 18, 19 . The evidence for the involvement of mTOR in the metabolic phenotype of exhaustion highlights the complex, dynamic balance between 'terminal' effector function and T cell persistence. While mTOR signaling might in part drive the cell away from mitochondrial metabolism toward anaerobic glycolysis, such changes are a necessary part of effector differentiation. Both are required for adequate ongoing T cell responses to persistent antigen, and the degree to which either path is inhibited affects the resulting phenotype 30 .
FoXo signals and exhaustion: death, survival and metabolism
FOXO transcription factors integrate signals from growth factors, substrate availability and inflammation and in turn regulate cellular growth, differentiation and metabolism 64 . The balance of FOXO signaling is clearly important in directing the differentiation of CD4 + regulatory T cells 65, 66 ; however, this balance also has an important cell-intrinsic role in the differentiation of CD8 + T cells and in directing the metabolic dysfunction of exhaustion. FOXO1 and FOXO3 are expressed by T cells 64 . The activity of FOXO1 promotes the survival and persistence T cells 67, 68 , while the activity of FOXO3 limits survival through pro-apoptotic effects mediated by Bim and PUMA [69] [70] [71] . Ablating the activity of FOXO3 (as in Foxo3 −/− CD8 + T cells) restricts the contraction phase after stimulation, which allows greater persistence of effector CD8 + T cells 72 ; this facilitates the clearance of chronic infection with LCMV 73 and control of human immunodeficiency virus in humans 74 . In contrast, FOXO1 signaling can maintain a pluripotent stem cell phenotype 75 and is required for the differentiation of effector CD8
+ T cells into a functional memory subset 76 through its downstream modulation of Tbet and Eomes 46 . It is therefore likely that the balance of FOXO signaling following TCR signaling will determine the balance of effector fate and cellular persistence during chronic antigen exposure.
However, the balance of FOXO-driven regulation is complex 64 , and a complete picture of its contribution to the metabolic dysfunction of exhaustion has yet to emerge, with several apparent contradictions persisting. For example, the role of FOXO3 in promoting apoptosis and effector differentiation is at odds with its apparent ability to maintain PGC1a expression and metabolic fitness (described below). Similarly, despite its role in promoting stem cell-like persistence, FOXO1 also seems to be necessary for differentiation of the terminally exhausted Tbet . These apparent discrepancies might reflect the complex integration by FOXO proteins of multiple other pathways, including hypoxic signaling 77 , metabolic pathways 78 and nutrient availability 79 . A future challenge will be to fully elucidate the complex role of these transcription factors in regulating metabolism during exhaustion.
PGC1a: regulation at the heart of metabolic exhaustion?
The ability to sustain energy production during rapid cellular proliferation requires mitochondrial biogenesis and the induction of gene-expression programs that result in the regulation of substrate uptake and use. This process is controlled by PGC1a 80 through control of both nuclear respiratory factors and the mitochondrial transcription factor Tfam 81 . It is now clear that PGC1a is central to the metabolic dysfunction of exhaustion in both LCMV models and tumor models. PGC1a shows reduced expression in both TILs 19 and T exh cells in the LCMV model 18 , while its overexpression limits mitochondrial dysfunction 18, 19 , which facilitates the emergence of polyfunctional CD8 + T cells 18 that drive infiltration and tumor regression 19 . The FOXO family of transcription factors, including both FOXO1 19, 82 and FOXO3 19, 83 , has been shown to promote PGC1a expression. Conversely, PGC1a expression is repressed by TCRdriven Akt signaling 82 , which in turn phosphorylates and inactivates FOXO1 and FOXO3 81 . Therefore persistent antigen-TCR signaling might serve to maintain Akt signaling and promote effector differentiation, but metabolic fitness will also be curtailed as FOXOdriven PGC1a expression is restricted (Fig. 4) .
It remains unclear, however, exactly how complex signals from multiple inhibitory receptors, including PD1, are integrated to modulate PGC1a levels and whether PGC1a is the only or the most important transcription factor in the modulation of early metabolic fitness. Absence of PD1 from the onset of a T cell response (through genetic deletion; Pdcd1 -/-) facilitates a later population expansion of exhausted cells in the absence of inhibitory signals that restrain cytotoxicity and terminal differentiation 53 . This demonstrates that PD1 is not essential for the development of exhaustion and that its expression at certain points might even limit such development. Genetic ablation of PD1 also results in higher expression of PGC1a 18 , which suggests that if PD1 is acting to preserve a degree of early bioenergetic fitness and to facilitate later survival despite ongoing stimulation, it probably is not doing so through PGC1a. Other data showing delayed tumor progression after blockade of PD1 in the absence of metabolic changes in TILs also suggest additional mechanisms 27 . Further studies will be needed to clarify the complexity of these signaling events.
autoimmune disease, metabolism and exhaustion T cell exhaustion regulates cellular immunity during the response to persistent antigenic stimulation, whether that is during chronic viral infection or in the tumor microenvironment. Exhaustion has also been inversely associated with a relapsing course of autoinflammatory disease, another example of reactivity of the immune system to persistent antigen (in this case, 'self '). A transcriptional signature specific for exhaustion correlates with a reduced rate of relapse in multiple diseases 61 , and features of T cell exhaustion correlate with a favorable response during immunotherapy of type 1 diabetes 84 . Such observations are consistent with the evolution of exhaustion as a mechanism for limiting immunopathology in the face of persistent TCR stimulation 17, 41 . A broadly similar phenotype of exhaustion is apparent in the distinct contexts of chronic viral infection and the tumor microenvironment. Such broad similarities are accompanied by specific differences, too, that are probably driven by distinct signals received in each context. It is likely that immunometabolism also has a key role in control of effector, persistent or exhausted T cell responses in autoimmunity.
It is clear that metabolic 'switches' are not only important for the initiation of T cell activation 13 but are also responsible for controlling an ongoing balance of effector-memory differentiation and exhaustion 18, 19 . Many studies have sought to directly compare measures of metabolic fitness in autoinflammatory disease and have typically made comparison with uninflamed, healthy control tissues and have sampled cells during or after active autoinflammation and immunosuppressive therapy 85 . In this context, it is not surprising to find altered metabolism as a secondary consequence of activation or therapeutic modulation of the immune system; indeed, it would be surprising not to find it. This highlights the need for appropriate control for variable proliferation and activation of the immune system in models and assays of immunometabolism, such as those used for LCMV models (in which adoptive transfer of small numbers of transgenic, LCMV-specific P14 T cells facilitates their direct comparison with host cells in an equivalent context 18, 53 ). Evidence supporting the proposal of a primary role for exhaustion-associated metabolic dysfunction in autoinflammatory disease is more limited.
Several genetic studies, however, have linked exhaustion-associated metabolic pathways to the onset and progression of various autoimmune phenotypes. Perhaps the most striking example is the recurrent association of a variant allele of the gene encoding the neutrophil cytosolic factor Ncf1 with the onset or severity of multiple autoinflammatory diseases 86 . Ncf1 is necessary for the activation of NADPH oxidase and the consequent production of superoxide during the respiratory burst. A decrease in ROS in the presence of a mutated allele leads to increased severity of and relapse in mouse models of multiple sclerosis and rheumatoid arthritis 86, 87 and shows association with multiple human autoimmune diseases 86 . Redox signaling can be controlled by PD1 signaling in T cells 88 , and the generation of ROS has been linked to the metabolic dysfunction of exhaustion 18, 19 . However, a direct link between Ncf1 function and exhaustion remains to be demonstrated.
The process of T cell exhaustion has thus far been associated with the progression rather than the onset of autoinflammatory disease 61, 84 , although exhaustion-associated inhibitory receptors have also been linked to broken tolerance 17 . A genome-wide association study of clinical outcome has identified a variant allele of the gene encoding FOXO3 that is associated with the progression of (but not susceptibility to)
Crohn's disease, rheumatoid arthritis and malaria 89 . Along with the association of T cell exhaustion with outcome in Crohn's disease 61 , this suggests a possible role for FOXO3-driven metabolic control of T cell exhaustion in autoinflammatory disease. However, the Crohn's disease-associated variant allele of the gene encoding FOXO3 has not yet been functionally tested in T cells, and a monocyte-intrinsic signaling pathway that directs production of the cytokines TGF-β and TNF is at least partly responsible for the association 90 .
Summary
During T cell activation, changes in cellular metabolism are inevitably needed to sustain the rapid changes in cell function. Increasing evidence suggests that metabolic changes are not simply a reaction to changes in T cell differentiation but instead drive them. It is now apparent that the integration of complex early signals from a cell's microenvironment is critical both for initiating activation and for regulating the nature of the 'downstream' differentiation. These signals direct the phenotypes not only of effector function and memory development but also of T cell exhaustion during chronic exposure to antigen.
In both chronic infection and tumor models in which exhaustion is apparent, metabolic changes in T cells occur rapidly, before the emergence of exhaustion itself, and are maintained into later stages. Multiple observations, therefore, have confirmed that cellular metabolism has a prominent role in the 'upstream' control of exhaustion rather than simply reflecting changes secondary to its development.
A wealth of evidence also indicates that signaling pathways that promote cellular persistence and/or survival can be dissociated from those that control effector function. Signals that promote aerobic glycolysis during activation might enhance effector differentiation, but this might be at the expense of memory potential. Conversely, the use of alternative pathways such as lipid metabolism at the expense of aerobic glycolysis might do the opposite. However, both processes are needed in parallel to appropriately mount an effective, durable T cell response to persistent antigen 30 . Thus, the metabolic balance between effector function and persistence represents another example of the 'Goldilocks' principle, in which effector and memory differentiation must be neither too much nor too little but 'just right' , in order to appropriately deal with infection without the development of immunopathology. Future challenges will include quantifying the extent to which each metabolic pathway contributes to T cell function and determining how each is controlled and how that knowledge might be harnessed to modulate metabolism and hence immunity. For this to be achieved, the understanding of T cell metabolism during human disease will have to catch up with the advances driven by informative mouse models of cancer and infection. However, modulating immunometabolism shows promise as a means of controlling chronic T cell responses in infection, cancer and autoinflammatory disease.
